ANS 03
Alternative Names: ANS-03Latest Information Update: 10 Jul 2026
At a glance
- Originator Avistone Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action ROS1 protein inhibitors; TrkA receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 17 Apr 2026 Adverse events, efficacy data from a phase I trial in Solid tumours presented at the 117th Annual Meeting of the American Association for Cancer Research (AACR-2026)
- 25 Apr 2025 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 06 Mar 2025 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy) in USA (PO) (NCT06716138)